Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, dou... by Catenacci, Daniel V T, Tebbutt, Niall C, Davidenko, Irina, Murad, André M, Al-Batran, Salah-Eddin, Ilson, David H, Tjulandin, Sergei, Gotovkin, Evengy, Karaszewska, Boguslawa, Bondarenko, Igor, Tejani, Mohamedtaki A, Udrea, Anghel A, Tehfe, Mustapha, De Vita, Ferdinando, Turkington, Cheryl, Tang, Rui, Ang, Agnes, Zhang, Yilong, Hoang, Tien, Sidhu, Roger, Cunningham, David

Get full text

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial by Nakagawa, Kazuhiko, Garon, Edward B, Seto, Takashi, Chiu, Chao-Hua, Novello, Silvia, Nadal, Ernest, Imamura, Fumio, Au, Kwok Hung, Moro-Sibilot, Denis, Enatsu, Sotaro, Zimmermann, Annamaria, Frimodt-Moller, Bente, Visseren-Grul, Carla, Reck, Martin, Chu, Quincy, Pujol, Jean-Louis, Moro-Sibilot, Denis, Lamour, Corinne, Bischoff, Helge, Kollmeier, Jens, Reck, Martin, Kimmich, Martin, Hammerschmidt, Stefan, Schütte, Wolfgang, Syrigos, Konstantinos, Ho, James Chung Man, Au, Kwok-Hung, Novello, Silvia, Ardizzoni, Andrea, Pasello, Giulia, Gregorc, Vanessa, Del Conte, Alessandro, Galetta, Domenico, Takahashi, Toshiaki, Nakagawa, Kazuhiko, Nishio, Makoto, Yoh, Kiyotaka, Seto, Takashi, Imamura, Fumio, Kumagai, Toru, Hotta, Katsuyuki, Goto, Yasushi, Hosomi, Yukio, Sakai, Hiroshi, Kim, Young Hak, Kurata, Takayasu, Daga, Haruko, Okamoto, Isamu, Satouchi, Miyako, Ikeda, Satoshi, Atagi, Shinji, Azuma, Koichi, Horio, Yoshitsugu, Tanaka, Hiroshi, Watanabe, Satoshi, Nogami, Naoyuki, Ozaki, Tomohiro, Koyama, Ryo, Kaneda, Hiroyasu, Tomii, Keisuke, Seike, Masahiro, Nishimura, Naoki, Kato, Terufumi, Saka, Hideo, Hirano, Katsuya, Nakahara, Yasuharu, Sugawara, Shunichi, Kim, Sang-We, Min, Young Joo, Kang, Jin-Hyoung, An, Ho Jung, Lee, Ki Hyeong, Kim, Jin-Soo, Lee, Gyeong-Won, Lee, Sung Yong, Udrea, Anghel Adrian, Juan-Vidal, Óscar, Nadal-Alforja, Ernest, Gil-Bazo, Ignacio, Ponce-Aix, Santiago, Paz-Ares, Luis, Rubio-Viqueira, Belén, Alonso Garcia, Miriam, Felip Font, Enriqueta, Fuentes Pradera, Jose, Lin, Meng-Chih, Su, Wu-Chou, Chang, Gee-Chen, Wei, Yu-Feng, Chiu, Chao-Hua, Cicin, Irfan, Goksel, Tuncay, Harputluoglu, Hakan, Ozyilkan, Ozgur, Henning, Ivo, Popat, Sanjay, Hatcher, Olivia, Acoba, Jared, Garon, Edward, Jung, Gabriel

Get full text

On the Regularization of Recursive Least-Squares Adaptive Algorithms Using Line Search Methods by Stanciu, Cristian-Lucian, Anghel, Cristian, Fîciu, Ionuț-Dorinel, Elisei-Iliescu, Camelia, Udrea, Mihnea-Radu, Stanciu, Lucian

Get full text

Molecular basis and therapeutic targets in prostate cancer: A comprehensive review by Militaru, Florentina Claudia, Militaru, Valentin, Crisan, Nicolae, Bocsan, Ioana Corina, Udrea, Anghel Adrian, Catana, Andreea, Kutasi, Eniko, Militaru, Mariela Sanda

Get full text

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab by Fuchs, Charles S, Tabernero, Josep, Tomášek, Jiří, Chau, Ian, Melichar, Bohuslav, Safran, Howard, Tehfe, Mustapha A, Filip, Dumitru, Topuzov, Eldar, Schlittler, Luis, Udrea, Anghel Adrian, Campbell, William, Brincat, Stephen, Emig, Michael, Melemed, Symantha A, Hozak, Rebecca R, Ferry, David, Caldwell, C William, Ajani, Jaffer A

Get full text

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer by Kim, Tae Won, Elme, Anneli, Kusic, Zvonko, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Valencia, Ricardo Villalobos, Krishnan, Srinivasan, Bilic, Ante, Manojlovic, Nebojsa, Dong, Jun, Guan, Xuesong, Lofton-Day, Catherine, Jung, A Scott, Vrdoljak, Eduard

Get full text

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarc... by Shah, Manish A, Udrea, Anghel Adrian, Bondarenko, Igor, Mansoor, Was, Sánchez, Raquel Guardeño, Sarosiek, Tomasz, Bozzarelli, Silvia, Schenker, Michael, Gomez-Martin, Carlos, Morgan, Carys, Özgüroğlu, Mustafa, Pikiel, Joanna, Kalofonos, Haralabos P, Wojcik, Elzbieta, Buchler, Tomas, Swinson, Daniel, Cicin, Irfan, Joseph, Mano, Vynnychenko, Ihor, Luft, Alexander Valerievich, Enzinger, Peter C, Salek, Tomas, Papandreou, Christos, Tournigand, Christophe, Maiello, Evaristo, Wei, Ran, Ferry, David, Gao, Ling, Oliveira, Joana M, Ajani, Jaffer A

Get full text

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) by Fayette, Jérôme, Wirth, Lori, Oprean, Cristina, Udrea, Anghel, Jimeno, Antonio, Rischin, Danny, Nutting, Christopher, Harari, Paul M, Csoszi, Tibor, Cernea, Dana, O'Brien, Paul, Hanley, William D, Kapp, Amy V, Anderson, Maria, Penuel, Elicia, McCall, Bruce, Pirzkall, Andrea, Vermorken, Jan B

Get full text

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer by Kim, Tae Won, Elme, Anneli, Kusic, Zvonko, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Valencia, Ricardo Villalobos, Krishnan, Srinivasan, Bilic, Ante, Manojlovic, Nebojsa, Dong, Jun, Guan, Xuesong, Lofton-Day, Catherine, Jung, A Scott, Vrdoljak, Eduard

Get full text

A comprehensive review on the molecular basis and therapeutic targets in prostate cancer by Militaru, Florentina Claudia, Militaru, Valentin, Crisan, Nicolae, Bocsan, Ioana Corina, Udrea, Anghel Adrian, Catana, Andreea, Kutasi, Eniko, Militaru, Mariela Sanda

Get full text

Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer by Kim, Tae Won, Elme, Anneli, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Valencia, Ricardo Villalobos, Krishnan, Srinivasan, Manojlovic, Nebojsa, Guan, Xuesong, Lofton-Day, Catherine, Jung, A. Scott, Vrdoljak, Eduard

Get full text

Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study) by Jérôme FAYETTE, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Danny Rischin, Christopher Nutting, Paul M. Harari, Tibor Csoszi, Dana Cernea, Paul O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan Baptist Vermorken

Get full text